Asuragen launches KRAS, BRAF mutational screening in CLIA laboratory Asuragen, Inc., a innovator in molecular diagnostics and nucleic acid-based pharmacogenomics solutions, today that it provides launched KRAS and BRAF mutational testing solutions in it is CAP-accredited CLIA laboratory announced. Asuragen’s KRAS and BRAF laboratory created tests had been designed in response to recently modified suggestions from the American Culture of Clinical Oncology and the National In depth Cancer tumor Network liquid tadalafil .
Oncology is among three therapeutic regions of concentrate recognized by AstraZeneca in March by CEO Pascal Soriot; the additional two are cardiovascular & metabolic disease; and respiratory, irritation & autoimmunity diseases. This content was reprinted from Genetic Engineering & Biotechnology Information with authorization from Mary Ann Liebert, Inc., publishers. Genetic Engineering & Biotechnology Information provides retained its position because the quantity 1 biotech publisher around the world since its start in 1981. GEN publishes a print edition 21 times a 12 months and has additional unique editorial content online, like news and analysis in addition to blogs, podcasts, webinars, polls, video clips, and program notes.